TTPH Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals to Present XERAVAâ„¢ (Eravacycline) and TP-6076 Data at IDWeek 2018

Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018

– Four Abstracts Selected for Poster Presentations –

– TP-6076 Featured in Oral Presentation –

WATERTOWN, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced it will have four posters and one oral presentation at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week (IDWeek) 2018, taking place October 3-7 in San Francisco, CA at the Moscone Center. Presentations will include data on XERAVA™ (eravacycline), the Company’s U.S. Food and Drug Administration approved treatment for complicated intra-abdominal infections (cIAI), which is also under review for regulatory approval by the European Commission for the treatment of cIAI. Additional data will be presented on TP-6076, the Company’s second-generation candidate to target MDR Gram-negative bacteria, which is currently in Phase 1 clinical testing.

The details for the data presentations at IDWeek are as follows:

XERAVA Poster Presentations

Poster title: Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections

Date and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PT

Location: S Poster Hall

Poster number:  1976

Session information: Poster Abstract Session: Clinical Trials

Poster title: Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 Studies of Complicated Intra-Abdominal Infections

Date and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PT

Location: S Poster Hall

Poster number:  1978

Session information: Poster Abstract Session: Clinical Trials

Poster title: Combined Microbiological Response Rates from Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4

Date and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PT

Location: S Poster Hall

Poster number:  1963

Session information: Poster Abstract Session: Clinical Trials

TP-6076 Oral Presentation

Presentation title: TP-6076 – Tetraphase Pharmaceuticals

Date and time: Thursday, October 4 from 2:00 p.m. – 3:15 p.m. PT

Location: N Hall D

Presentation number: 837

Speaker: Larry Tsai, M.D.

Session information: Exploring the Antibiotic Pipeline 2018

TP-6076 Poster Presentation

Poster title: Safety, Tolerability and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 Study

Date and time: Friday, October 5 from 12:30 p.m. – 1:45 p.m. PT

Location: S Poster Hall

Poster number: 1371

Session information: Poster Abstract Session: Novel Agents

Additional Activities

  • Tetraphase will host a XERAVA exhibit booth (#324) at IDWeek 2018 during exhibit hours: Thursday, October 4; from 11:45 a.m. – 6:00 p.m. PT; Friday, October 5 from 10:00 a.m. – 4:00 p.m. PT; and Saturday, October 6 from 10:00 a.m. – 2:00 p.m. PT. Tetraphase Medical Affairs also will be present at booth #322 during exhibit hours.

     
  • Tetraphase has provided an independent educational grant in support of a Continuing Medical Education Lunch Symposium entitled “Emerging Options for Complicated Gram-Negative Infections: Considerations for Intra-Abdominal and Urinary Tract Infections.” It will take place on Wednesday, October 3, from 11:00 a.m. – 1:00 p.m. PT at Moscone South 206-208.

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the IDWeek website at  

About XERAVA  

XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

Important Safety Information

To report suspected adverse reactions, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or at 1-800-FDA-1088 or /medwatch.

Please see full prescribing information for XERAVA at

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections (cIAI) by the U.S. Food and Drug Administration and under review for marketing application authorization approval by the European Commission for the treatment of cIAI. The Company’s pipeline also includes TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit for more company information.

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether eravacycline will be successfully distributed and marketed and other regulatory and commercial risk factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the period ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018. In addition, the forward-looking statements included in this press release represent our views as of September 19, 2018. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Media and Investor Contact:

Tetraphase Pharmaceuticals

Jennifer Viera

617-600-7040

 

EN
19/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc: 1 director sold

A director at Tetraphase Pharmaceuticals Inc sold 15,031 shares at 2.190USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

 PRESS RELEASE

Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success...

Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference WATERTOWN, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 9:40 a.m. ET at the Mandarin Oriental Hotel in New York City. A live audio webca...

 PRESS RELEASE

Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Result...

Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update XERAVATM (eravacycline) Now Available to Hospitals in the United States Conference Call Today at 4:30 p.m. Eastern Time WATERTOWN, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended September 30, 2018 and provided a corporate update. “During the third quarter of 2018, we reach...

 PRESS RELEASE

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. ET at Lotte New York Palace Hotel in New York City. Mr. Macdonald also will participate in a fireside chat at t...

 PRESS RELEASE

Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Result...

Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will host a conference call at 4:30 p.m. ET on Thursday, November 8, 2018 to discuss third quarter financial results and provide a general corporate update. The conference call may be accessed by dialing 844-831-4023 (U.S. and Canada) or 731-256-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch